ASTRAZENECA PLC (AZN)
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
📈 **POSITIVE** • Medium confidence analysis (73%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business